Audit a URL →

Sign in Sign up free

Loading…

Weekly · Sunday Morning

Five longevity claims.
Worth your time.
Every Sunday.

Last Sunday

Rapamycin extends mouse lifespan 9–14%
NAD+ precursors reverse aging in humans
Blue-light glasses improve sleep quality
Walking 10 min after meals blunts glucose
Verdict change — caffeine half-life downgraded

5 audits·1 verdict change·0 affiliate links·Every Sunday

Joining 1,247 readers — founders, MDs, and longevity-obsessed people who fact-check their own health decisions.

Browse

Decisions Claims Content Creators

Product

Audit a URL Sunday roundup API (soon)Pricing

About

FAQ Methodology Editorial Standards Corrections Press & brand RSS feed

Legal

Terms of Service Privacy Policy DMCA

Finally, something serious in this space.
Because we actually read the papers.

© 2026 Whalespan. Independent, evidence-graded longevity.

GLP-1 agonists and the willpower myth — Whalespan

Content›Video›GLP-1 agonists and the willp…

GLP-1 agonists and the willpower myth

Peter Attia5m · 2025-02-25

Claims Made

11

Claims Supported

3

Support Rate

27%

Support rate

3 of 11 claims supported

3 supported8 partial / not

Claims from this content

6

◐Partially SupportedMore data is available regarding weight regain after stopping GLP-1 and GIP agonist drugs.✓Well SupportedSome patients who discontinue GLP-1 agonists do not regain weight if they have implemented effective training and nutrition strategies.◐Partially SupportedThe high cost of GLP-1 agonists poses a significant economic challenge to the healthcare system.✕Not SupportedGenetics play a significant role in body habitus and weight regulation, making willpower not the sole factor in weight loss.Partially Supported

More from Peter Attia

Peter Attia on Zone 2 Cardio

Peter Attia on Rapamycin (with Matt Kaeberlein)

Attia walks back the clinic protocol: too aggressive for healthy adults

Discussion

Native comments, Twitter mentions, and Reddit threads about this content — surfaced together so the conversation isn't fragmented across platforms.

M

Share your read of this content…

Posting publicly as you · linked to your social profiles

Sort by:

AV

A. Volkovreader

4h

Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.

NP

N. Park

2d

Would love a "what would change this verdict" RSS feed. Sign me up if it exists.

◐

Individuals without type 2 diabetes seeking to lose ~15 pounds are unlikely to qualify for insurance coverage of GLP-1 agonists.

◐Partially SupportedFor individuals with a genetic predisposition to weight gain, GLP-1 agonists can act as a counterforce.